User login
Key clinical point: A focal boost to external beam radiotherapy (EBRT) improves local failure-free survival (LFS) and regional/distant metastasis-free survival (rdMFS) in patients with localized high-risk prostate cancer.
Major finding: At a median follow-up of 72 months, focal boost improved LFS (adjusted hazard ratio [aHR], 0.33; P = .01) and rdMFS (aHR, 0.56; P = .02). A higher dose to the tumor resulted in lower LFS and rdMFS rates.
Study details: A phase 3, multicenter, randomized controlled FLAME trial of 571 patients with intermediate- or high-risk localized prostate cancer who were randomly assigned to receive EBRT with or without an additional boost of up to 95 Gy to the macroscopic tumor.
Disclosures: This study was supported by the Dutch Cancer Society. The authors reported no conflict of interests.
Source: Groen VH et al. Eur Urol. 2021 Dec 22. doi: 10.1016/j.eururo.2021.12.012.
Key clinical point: A focal boost to external beam radiotherapy (EBRT) improves local failure-free survival (LFS) and regional/distant metastasis-free survival (rdMFS) in patients with localized high-risk prostate cancer.
Major finding: At a median follow-up of 72 months, focal boost improved LFS (adjusted hazard ratio [aHR], 0.33; P = .01) and rdMFS (aHR, 0.56; P = .02). A higher dose to the tumor resulted in lower LFS and rdMFS rates.
Study details: A phase 3, multicenter, randomized controlled FLAME trial of 571 patients with intermediate- or high-risk localized prostate cancer who were randomly assigned to receive EBRT with or without an additional boost of up to 95 Gy to the macroscopic tumor.
Disclosures: This study was supported by the Dutch Cancer Society. The authors reported no conflict of interests.
Source: Groen VH et al. Eur Urol. 2021 Dec 22. doi: 10.1016/j.eururo.2021.12.012.
Key clinical point: A focal boost to external beam radiotherapy (EBRT) improves local failure-free survival (LFS) and regional/distant metastasis-free survival (rdMFS) in patients with localized high-risk prostate cancer.
Major finding: At a median follow-up of 72 months, focal boost improved LFS (adjusted hazard ratio [aHR], 0.33; P = .01) and rdMFS (aHR, 0.56; P = .02). A higher dose to the tumor resulted in lower LFS and rdMFS rates.
Study details: A phase 3, multicenter, randomized controlled FLAME trial of 571 patients with intermediate- or high-risk localized prostate cancer who were randomly assigned to receive EBRT with or without an additional boost of up to 95 Gy to the macroscopic tumor.
Disclosures: This study was supported by the Dutch Cancer Society. The authors reported no conflict of interests.
Source: Groen VH et al. Eur Urol. 2021 Dec 22. doi: 10.1016/j.eururo.2021.12.012.